Clinical applications of adipose-derived stromal vascular fraction in veterinary practice
Adipose tissue-derived stromal vascular fraction (AdSVF) comprises a heterogeneous cell population, including the multipotent mesenchymal stem cells, hematopoietic stem cells, immune cells, endothelial cells, fibroblasts, and pericytes. As such, multipotent adipose tissue-derived mesenchymal stem cells (AdMSCs), are one of the important components of AdSVF. Commonly used techniques to harvest AdSVF involve enzymatic or non-enzymatic methods. The enzymatic method is considered to be the gold standard technique due to its higher yield. The cellular components of AdSVF can be resuspended in normal saline, platelet-rich plasma, or phosphate-buffered saline to produce a ready-to-use solution. Freshly isolated AdSVF has exhibited promising osteogenic and vasculogenic capacity. AdSVF has already been proven to possess therapeutic potential for osteoarthritis management. It is also an attractive therapeutic option for enhancing wound healing. In addition, the combined use of AdSVF and platelet-rich plasma has an additive stimulatory effect in accelerating wound healing and can be considered an alternative to AdMSC treatment. It is also widely used for managing various orthopaedic conditions in clinical settings and has the potential for regenerating bone, cartilage, and tendons. Autologous AdSVF cells are used along with bone substitutes and other biological factors as an alternative to conventional bone grafting techniques owing to their promising osteogenic and vasculogenic capacity. It can also be used for treating osteonecrosis, meniscus tear, chondromalacia, and tendon injuries in veterinary practice. It has several advantages over in vitro expanded AdMSC, including precluding the need for culturing, reduced risk of cell contamination, and cost-effectiveness, making it ideal for clinical use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The veterinary quarterly - 42(2022), 1 vom: 12. Dez., Seite 151-166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharun, Khan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adipose tissue |
|---|
| Anmerkungen: |
Date Completed 09.08.2022 Date Revised 12.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/01652176.2022.2102688 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343614367 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343614367 | ||
| 003 | DE-627 | ||
| 005 | 20231226020846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/01652176.2022.2102688 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343614367 | ||
| 035 | |a (NLM)35841195 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharun, Khan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical applications of adipose-derived stromal vascular fraction in veterinary practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2022 | ||
| 500 | |a Date Revised 12.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Adipose tissue-derived stromal vascular fraction (AdSVF) comprises a heterogeneous cell population, including the multipotent mesenchymal stem cells, hematopoietic stem cells, immune cells, endothelial cells, fibroblasts, and pericytes. As such, multipotent adipose tissue-derived mesenchymal stem cells (AdMSCs), are one of the important components of AdSVF. Commonly used techniques to harvest AdSVF involve enzymatic or non-enzymatic methods. The enzymatic method is considered to be the gold standard technique due to its higher yield. The cellular components of AdSVF can be resuspended in normal saline, platelet-rich plasma, or phosphate-buffered saline to produce a ready-to-use solution. Freshly isolated AdSVF has exhibited promising osteogenic and vasculogenic capacity. AdSVF has already been proven to possess therapeutic potential for osteoarthritis management. It is also an attractive therapeutic option for enhancing wound healing. In addition, the combined use of AdSVF and platelet-rich plasma has an additive stimulatory effect in accelerating wound healing and can be considered an alternative to AdMSC treatment. It is also widely used for managing various orthopaedic conditions in clinical settings and has the potential for regenerating bone, cartilage, and tendons. Autologous AdSVF cells are used along with bone substitutes and other biological factors as an alternative to conventional bone grafting techniques owing to their promising osteogenic and vasculogenic capacity. It can also be used for treating osteonecrosis, meniscus tear, chondromalacia, and tendon injuries in veterinary practice. It has several advantages over in vitro expanded AdMSC, including precluding the need for culturing, reduced risk of cell contamination, and cost-effectiveness, making it ideal for clinical use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mesenchymal stem cells | |
| 650 | 4 | |a adipose tissue | |
| 650 | 4 | |a bone healing | |
| 650 | 4 | |a enzymatic digestion | |
| 650 | 4 | |a regenerative medicine | |
| 650 | 4 | |a review | |
| 650 | 4 | |a stromal vascular fraction | |
| 650 | 4 | |a veterinary medicine | |
| 700 | 1 | |a Jambagi, Kaveri |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Gugjoo, Mudasir Bashir |e verfasserin |4 aut | |
| 700 | 1 | |a Pawde, Abhijit M |e verfasserin |4 aut | |
| 700 | 1 | |a Tuli, Hardeep Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Dhama, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Amarpal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The veterinary quarterly |d 1979 |g 42(2022), 1 vom: 12. Dez., Seite 151-166 |w (DE-627)NLM012965510 |x 1875-5941 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:1 |g day:12 |g month:12 |g pages:151-166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/01652176.2022.2102688 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 1 |b 12 |c 12 |h 151-166 | ||